A Single Point of Access for frontline practitioners
PAINWeekEnd Philadelphia 2019 | Saturday 10/26/19
This is a 1-day meeting and will provide 6 CE/CME credits.
Practicing Healthcare Professionals: $129
In order to maintain the clinical nature of the conference, nonclinicians—including, but not limited to, office managers, billing specialists, receptionists, and administrative staff; guests, spouses, friends, and/or family members—may not attend PAINWeekEnd.
Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.
DoubleTree by Hilton Hotel Philadelphia Center City
237 S Broad Street
Philadelphia, PA 19107
Get Directions using Google Maps
Faculty and courses are subject to change. Please refer to the online agenda below for the most recent course descriptions.
To view the agenda below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.
*not certified for credit
Coffee will be served.
Individuals who suffer from chronic pain often present with significant medical and psychiatric comorbidities that can exacerbate the pain experience and contribute to a further erosion of quality of life and disability. In this current climate of reducing the reliance on opioids or opioid sparing it is essential that clinicians effectively and efficiently identify and manage these comorbidities. This presentation will provide an overview of the prevalence of common comorbidities, assessment strategies, and pharmacologic and nonpharmacologic interventions in patients with chronic pain.
Breakfast will be served.
Sponsored by Teva Pharmaceuticals.
There is much controversy around many aspects of pain treatment, and compelling arguments have focused on both sides of the fence regarding appropriate opioid use and prescribing, legalization of marijuana, and the safety of cox-2 inhibitors. In all 3 cases, there are issues associated with strong positions, although the evidence, when put into practice, is less black and white. For each topic, we will evaluate current literature and debate the clinical, legal, and ethical controversies surrounding recent developments in pain management. Attendees will get a better understanding as presenters debate evidence based application of the CDC guidelines in various clinical settings, evaluate clinical and ethical concerns regarding marijuana for medicinal or recreational use, and take a critical look at the literature and its application when using cox-2 inhibitors for treating pain.
Despite high prevalence and seemingly continuous attention, the clinical challenges associated with assessing, treating, and managing patients with chronic pain continue to persist. Many different forces are at play and responsible for this frequently frustrating situation and, as is often the case, the person with the most at risk is the patient with chronic pain. There is no deficit of opinions for possible solutions to this problem. In fact, the number of potential solutions seems to increase each year, all with the intent of helping pain care be more safe and effective, and most trying to stem the negative consequences of abuse, misuse, and diversion of prescription pain medications. Clinicians have had to juggle these good intentions along with the fear of regulatory scrutiny. This course will present and detail the variety of current regulatory forces that need to be considered in clinical practice; how they can potentially impact clinical decisions regarding chronic pain; and how they can be negotiated. A number of regulatory agencies are now “sitting at the pain management table” for the foreseeable future and it is critical to navigate the waters without sacrificing that most important stakeholder: the patient.
Lunch will be served.
Sponsored by Legally Mine.
Surveys of healthcare providers indicate that one of the most distressing features of clinical practice is that of patient nonadherence. Its incidence in pain medicine is concerning: over 50% of patients with chronic noncancer pain are nonadherent with their prescribed exercise treatment and up to 62% of patients with chronic noncancer pain are nonadherent to psychopharmacological treatment. Nonadherence is a critical issue, not only because it undermines treatment effectiveness, but because it can waste limited resources and be dangerous, especially regarding medications. Although promoting adherence is an important component of clinical practice, unfortunately it’s rarely taught in medical, nursing, or dental school. This presentation will review the ethical considerations and current models and predictors of adherence in pain care and provide practical tools to improve adherence to medication management, exercise, nutrition, and weight loss.
Refreshments will be served.
Sponsored by Parkway Clinical Laboratories.
With our current climate of opioid overuse and increasing opioid related deaths, alternatives to pure mu opioids are necessary. Buprenorphine, an important weapon in the arsenal for management of substance use disorder, is now rising in popularity as an opioid option for chronic pain. Evidence has demonstrated efficacy for various chronic pain conditions with less risk of adverse effects, such as the development of tolerance and respiratory depression. With increasing utilization, patients on chronic buprenorphine therapy are now more frequently being admitted to hospitals with severe acute pain due to surgery or trauma. A partial opioid agonist, buprenorphine has unique pharmacokinetic properties that differ from pure mu opioid agonists. Challenges with pain control can occur when acute pain treatment with a pure opioid is used in patients receiving buprenorphine due to its strong affinity to the mu receptor. This session will review the unique characteristics of buprenorphine and offer options for treatment of severe acute pain in patients receiving buprenorphine therapy.
There is a significant amount of media, political, and public attention paid to the opioid crisis/opioid epidemic in the United States today. With the seemingly ever-increasing number of opioid-related overdoses and fatalities, there has been a feverish push by stakeholders to diminish the amount of opioids prescribed in order to help stem these worrisome trends. Unfortunately, there may be a lack of focus regarding the true definition and characterization of the opioid epidemic. There may also be a rush to judgment about the role of appropriately prescribed opioid analgesics in the addiction crisis we face today as well. This presentation will discuss the roles and statistics of both prescription and illicit opioids (namely heroin and fentanyl) in today’s “opioid overdose epidemic” with the intention of clarifying important differences and similarities between these competing epidemics including concerns and clinical considerations specific to each of them. Additionally, this program will examine and identify how these medications and drugs share potentially tragic adverse effect profiles in many cases. However, it is important for clinicians to make sure that appropriate chronic pain patients that may be candidates for opioid analgesic therapy aren’t penalized, and still get the treatment that they deserve.
To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!